NH HB1735

Expands New Hampshire's Right to Try Act to include patients with "qualifying severe illness" (chronic and debilitating conditions) in addition to those with terminal illness

Broadens access to drugs, biologics, and devices not yet approved by the FDA, removing the previous requirement that treatments must have completed phase one clinical trials

Provides immunity from lawsuits for manufacturers, pharmacists, health care providers, and facilities treating patients under the act, provided they meet specified conditions and do not engage in willful or reckless misconduct

Allows manufacturers to provide treatments without compensation or charge patients for the drug, biologic, or device, and permits requiring patient participation in data collection

Protects physicians from losing their licenses and prevents the Department of Health and Human Services from taking action against facilities based primarily on participation in treatments under this chapter